Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino [2,3-F]quinoline as 5-HT1A antagonists

Abstract

Compounds of the formula are useful for treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia, and are also useful for the treatment of disorders such as anxiety, aggression and stress, and for the control of various physiological phenomena, such eating disorders, disorders of thermoregulation, and sleep and sexual dysfunction.

1 - 16 . (canceled)  
   
   
       17 . A method of treating a subject suffering from a condition selected from the group consisting of anxiety, aggression and stress which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I  
     
       
         
         
             
             
         
       
       wherein  
       R 1  is hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;  
       R 2  is hydrogen, hydroxy, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, or alkyl of one to six carbon atoms;  
       R 3  is phenyl, naphthyl, anthracyl, phenanthryl, pyridyl, pyrimidyl, triazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, indolyl, imidazolyl, benzofuryl, benzothienyl, oxazolyl, or thiazolyl, each optionally substituted with one to three substituents selected from hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkoxy of one to six carbon atoms, and alkyl of one to six carbon atoms;  
       X is N or CR 4 ;  
       Y is N or CH; and  
       R 4  is hydrogen or alkyl of one to six carbon atoms;  
       or a pharmaceutically acceptable salt thereof.  
     
   
   
       18 . The method of  claim 17  wherein the subject is a human.  
   
   
       19 . A method of treating a subject suffering from a condition selected from the group consisting of eating disorders, disorders of thermoregulation, sleep dysfunction and sexual dysfunction which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I  
     
       
         
         
             
             
         
       
       wherein  
       R 1  is hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;  
       R 2  is hydrogen, hydroxy, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, or alkyl of one to six carbon atoms;  
       R 3  is phenyl, naphthyl, anthracyl, phenanthryl, pyridyl, pyrimidyl, triazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, indolyl, imidazolyl, benzofuryl, benzothienyl, oxazolyl, or thiazolyl, each optionally substituted with one to three substituents substitutents selected from hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkoxy of one to six carbon atoms, and alkyl of one to six carbon atoms;  
       X is N or CR 4 ;  
       Y is N or CH; and  
       R 4  is hydrogen or alkyl of one to six carbon atoms;  
       or a pharmaceutically acceptable salt thereof.  
     
   
   
       20 . The method of  claim 19  wherein the subject is a human.  
   
   
       21 . A method of treating a subject suffering from depression comprising providing to the subject suffering from said condition, an antidepressant amount of a serotonin selective reuptake inhibitor and an amount of a compound of formula I  
     
       
         
         
             
             
         
       
       wherein  
       R 1  is hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;  
       R 2  is hydrogen, hydroxy, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, or alkyl of one to six carbon atoms;  
       R 3  is phenyl, naphthyl, anthracyl, phenanthryl, pyridyl, pyrimidyl, triazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, indolyl, imidazolyl, benzofuryl, benzothienyl, oxazolyl, or thiazolyl, each optionally substituted with one to three substituents selected from hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkoxy of one to six carbon atoms, and alkyl of one to six carbon atoms;  
       X is N or CR 4 ;  
       Y is N or CH; and  
       R 4  is hydrogen or alkyl of one to six carbon atoms;  
       or a pharmaceutically acceptable salt thereof,  
       said amount of compound of Formula I being effective to increase the onset of antidepressant efficacy.  
     
   
   
       22 . The method of  claim 21  wherein the subject is a human.  
   
   
       23 . The method of  claim 21  wherein the serotonin selective reuptake inhibitor is selected from the group consisting of sertraline, fluvoxamine, paroxetine, venlafaxine, duloxetine, citalopram, fluoxetine, and metabolites of sertraline, fluvoxamine, paroxetine, venlafaxine, duloxetine, citalopram, and fluoxetine.  
   
   
       24 - 26 . (canceled)